The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire…
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB),…
KENTFIELD, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc., a clinical stage medical device company, today announced that…
Topline results expected in 2H 2024CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical…
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing…
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria…
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase…
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at…
Podocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure ResultsELX-02 treatment improved podocyte foot process effacement in all three patients…
Topline data results from the STRIDE study are expected in December 2023IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo…